Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06439-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Eeva Martelin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. eeva.martelin@hus.fi. Hauptthemen laut MEDLINE: Graft vs Host Disease, Nitriles, Pyrimidines, Pyrazoles. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In Europe, ruxolitinib is the first approved treatment for corticosteroid-refractory/-dependent acute or chronic graft-versus-host disease (aGvHD/cGvHD). This retrospective, non-interventional study evaluated the real-world efficacy and safety of ruxolitinib in 56 adult aGvHD patients treated with ruxolitinib from January 2019 through August 2021 in Finland. The primary endpoint was best overall response rate (ORR) at any time. The main secondary endpoints were the time to response and loss of response, overall survival (OS), and corticosteroid discontinuation. The follow-up lasted until death/August 2022. The ORR was 91% (95% CI: 83.5–98.5; complete response [CR], 69.6%; partial response [PR], 21.4%). The median time to best response was 28 days (95% CI: 21–38). The median time to loss of response due to aGvHD progression, cGvHD, or a relapse-related death was 8.8 months (95% CI: 3.3–not reached). The most common cause of discontinuation was the achievement of response (64.3%). Two-thirds of the corticosteroid-treated patients discontinued corticosteroids before the end of follow-up; one-third were on a median dose of 0.2 mg/kg (IQR: 0.1–0.5) at the end of follow-up. The three-year OS was 64.1% (95% CI: 48.2–76.3). Ruxolitinib appears effective and safe in real-world practice. The presented data is in line with the results of clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. eeva.martelin@hus.fi.
- Turku University Hospital, Hospital District of Southwest Finland, Turku, Finland.
- Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
- Novartis Finland Oy, Espoo, Finland.
- Medaffcon Oy, Espoo, Finland.
Zitieren
APA
Martelin, E., Kuikka, A., Rajala, H., Ruohonen, T., Mönkkönen, H., Vikkula, J., Uusi-Rauva, K., Salmenniemi, U., & Itälä-Remes, M. (2025). Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland. Annals of Hematology. https://doi.org/10.1007/s00277-025-06439-2
Vancouver
Martelin E, Kuikka A, Rajala H, Ruohonen T, Mönkkönen H, Vikkula J, et al. Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland. Annals of Hematology. 2025. doi:10.1007/s00277-025-06439-2
BibTeX
@article{Martelin2025,
author = {Martelin, Eeva and Kuikka, Arttu and Rajala, Hanna and Ruohonen, Tuomas and Mönkkönen, Hannu and Vikkula, Johanna and Uusi-Rauva, Kristiina and Salmenniemi, Urpu and Itälä-Remes, Maija},
title = {Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06439-2}
}
EUVIMED